Trial Profile
The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Nafamostat (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- 23 Jan 2013 New trial record